MiNK Therapeutics, Inc. (INKT) Stock Price & Analysis
MiNK Therapeutics, Inc. (INKT) closed at USD 10.71 on Friday, October 23, 2026, up 6.46% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.06; the Oct 23, 2026 session ranged USD 10.18–11.52 on volume of 29,242 shares. Market capitalization is $54.65M, with a 52-week range of USD 8.48–16.93 (NCM). Source: Nexqual, retrieved October 24, 2026 at 01:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INKT.md
Key facts (INKT)
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $92K; 2 not under a Rule 10b5-1 plan ($92K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 42.5 (range 35–50).
- Total return with dividends: 1Y -28.5% vs S&P 500 +13.4%; 5Y -94.0% vs S&P 500 +76.9%.
- Next earnings: 2026-11-12, EPS estimate USD -0.5, revenue estimate $875K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INKT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$28.4M | -$30.9M | -$22.9M | -$11.3M | -$12.6M | -$12.0M |
| Net income | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M | -$11.4M |
| EPS (diluted) | -$11.60 | -$8.30 | -$6.54 | -$2.86 | -$2.93 | — |
| Free cash flow | -$13.1M | -$19.1M | -$15.8M | — | — | — |
| Cash + short-term investments | $38.9M | $19.6M | $3.4M | $4.6M | $13.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (INKT)
Earnings yield -20.79%
Insider sales (SEC Form 4, open-market, last ~7 months) (INKT)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | Chief Executive Officer | 6,938 | $73K | 8.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Ryan Barbara | Director | 1,500 | $19K | 6.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (INKT)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 42.5 (low 35, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | B. Riley Securities | Target raised | Buy | $43 → $50 |
Total return (dividends reinvested) (INKT)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -28.5% | -94.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -28.6% | -43.1% |
| Volatility (annualized) | 71.5% | 143.5% |
| Max drawdown | -42.8% (Oct 2025→Mar 2026) | -97.4% (Nov 2021→Dec 2024) |
INKT suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AGENUS INC (AGEN) | “Our Intellectual Property Assignment and License Agreement with Agenus(September 2021), providing access to a portfolio of immuno-oncology assets and adjuvants to support combination strategies.” |
| Competitor | Johnson & Johnson (JNJ) | “Key competitors developing autologous CAR-T and TCR-based therapies include large pharmaceutical and biotechnology companies such as Bristol-Myers Squibb (including former Celgene and Juno Therapeutics assets), Gilead Sciences, Johnson & Johnson, Novartis, AstraZeneca, and BioNTech.” |
Quoted from the company's 10-K filed Mar 31, 2026.
Companies that name INKT in their SEC reports
| Relationship to INKT | Company | Filing | Sentence |
|---|---|---|---|
| partner | AGENUS INC (AGEN) | 10-K Mar 16, 2026 | “Furthermore, our ability to generate cash from operations is dependent in part on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensing and partnering relationships and/or successful development, approval and commercialization of product candidates, including through our antibody programs and platforms, MiNK's adoptive cell therapy programs, and ou…” |
INKT company outlook (results filed Aug 13, 2026)
- “Additional data are expected in early 2027.”
Quoted word-for-word from the SEC 8-K results press release.
INKT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.50 | $-0.63 | -20.6% | $875,000 | 2 |
| Next quarter (ends Dec 2026) | $-0.51 | $-0.66 | -22.7% | $1.0M | 2 |
| Current fiscal year (ends Dec 2026) | $-2.21 | $-2.46 | -10.4% | $1.9M | 2 |
| Next fiscal year (ends Dec 2027) | $-2.19 | $-2.85 | -23.3% | $2.8M | 2 |
Key Statistics (as of October 24, 2026 at 01:36 UTC)
| Price | USD 10.71 |
|---|---|
| Change | ▲ 6.46% (up) |
| Previous Close | USD 10.06 |
| Open | USD 10.64 |
| Day Range | USD 10.18 – 11.52 |
| 52-Week Range | USD 8.48 – 16.93 |
| Volume | 29,242 shares |
| Market Cap | $54.65M |
| Exchange | NCM |
Technical Analysis (INKT)
Nexqual's technical model rates INKT "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 01:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 48.43 (neutral) |
| vs SMA50 | Below (USD 11.43) |
| MACD | -0.44 (negative) |
Analyst Ratings (INKT)
Wall Street analysts rate INKT "Buy" based on 2 analysts, with a mean price target of USD 42.5 (range USD 35–50), per Nexqual as of October 24, 2026 at 01:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 42.5 |
| High Target | USD 50 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (INKT)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.5 |
| Revenue Estimate | $875,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.62 vs est -0.6 ▼ miss |
| 2026-03-31 | USD -0.57 vs est -0.77 ▲ beat |
| 2025-12-31 | USD -0.56 vs est -0.68 ▲ beat |
| 2025-09-30 | USD -0.65 vs est -0.86 ▲ beat |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Financials & Fundamentals (INKT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.23 |
| Total Cash | $8.81M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Financial Health Score (INKT)
Nexqual rates MiNK Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 01:36 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (INKT)
| Insider Ownership | +59.69% |
|---|---|
| Institutional Ownership | +4.00% |
| Shares Outstanding | 5.10M |
| Float | 2.06M |
| Short % of Float | +1.94% |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Leadership (INKT)
MiNK Therapeutics, Inc. is led by Jennifer S. Buell, Co-Founder, President, CEO & Director, per Nexqual as of October 24, 2026 at 01:36 UTC.
| Co-Founder, President, CEO & Director | Jennifer S. Buell |
|---|---|
| Executive Chairman | Garo H. Armen |
Major Backers & Investors (INKT)
Notable institutional backers of MiNK Therapeutics, Inc. include DnB Asset Management AS, Longbow Finance Sa, Citadel, according to Nexqual as of October 24, 2026 at 01:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DnB Asset Management AS | 1.08% |
| Longbow Finance Sa | 0.33% |
| Citadel | 0.3% |
| Fidelity | 0.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.51% |
| Geode Capital | 0.31% |
| BlackRock | 0.26% |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
From MiNK Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our discovery efforts are focused applying our proprietary technologies to build a broad pipeline of engineered iNKT cells, including CRs, CAR-iNKTs (such as MiNK-215 (FAP-CAR-iNKT) and MiNK-413 (BCMA-CAR-iNKT)), and INKT cell engager technology.
- With our vertically integrated manufacturing capabilities and experienced team, we are accelerating the development of accessible, off-the-shelf iNKT-based therapies with transformative potential across oncology, critical pulmonary immune failure, and GvHD.
- Build a pipeline of engineered iNKT cell therapies: Apply our proprietary technologies to develop next-generation engineered iNKT candidates, including MiNK-215 (FAP CAR-iNKT), with IND-enabling activities ongoing, and additional programs targeting both oncology and fibrosis.
- Scale manufacturing and operational capabilities: Continue to enhance our proprietary, closed-system manufacturing processes to improve scalability, reduce cost of goods, and increase flexibility and speed of production.
Partnerships
- As part of our collaboration with Agenus, we are evaluating agenT-797 in combination with Agenus' botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or GEJ adenocarcinoma through a Phase 2 investigator sponsored study.
Legal & Regulatory Risks (Item 1A, quoted)
- The regulatory landscape that will govern any product candidates we may develop is uncertain and may change.
- Any failure to comply with laws and regulations could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, or we may fail to satisfy certain arrangements with governmental authorities.
- Laws and regulations governing our international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us implement costly compliance programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| ABVX | Abivax SA | USD 88.01 | ▼ 2.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt